Lin Health, a provider of behavioral care for chronic pain recovery, has raised an oversubscribed $11 million Series A financing round to accelerate growth of its virtual, physician-led chronic pain treatment program and expand partnerships with health systems, clinics, and payers. The round was led by Proofpoint Capital, a venture firm formed by healthcare operators, with participation from new investors Osage Venture Partners and NewHealth Ventures. Existing backers also participated, including aMoon, Mayo Clinic, Saban Ventures, Shoni Health Ventures, and Viola Ventures. As part of the financing, Proofpoint Capital’s Dan Goldsmith is joining Lin Health’s board.
Lin Health is positioning its platform as a first-line, non-opioid approach to chronic pain care that is designed to address pain at its root in the nervous system. The company said its virtual program is coach-supported and physician-led, engages patients multiple times per week, and is grounded in decades of clinical research and aligned with national guidelines for chronic pain management. Lin Health said it treats a range of chronic pain-related conditions, including migraines, irritable bowel syndrome, and back and joint pain.
The company emphasized the size of the market and the strain chronic pain places on the healthcare system, stating that chronic pain costs more than cancer and diabetes combined and estimating annual costs at $635 billion. Lin Health also said at least one in five doctor visits are tied to pain, describing chronic pain as a major blind spot in U.S. healthcare.
Lin Health said its model is built to support longitudinal treatment while reducing burdens on providers by leveraging proprietary technology and AI to scale operations and integrate more deeply across the healthcare ecosystem, without increasing administrative costs. The company said its program is accessible to more than 60 million covered Americans through nationwide payer coverage.
Lin Health said the Series A proceeds will be used to drive product innovation, expand go-to-market efforts, strengthen clinically integrated partnerships, and accelerate its push to become a widely adopted first-line option for chronic pain care.
KEY QUOTES:
“This milestone reflects the confidence of our investors and the urgency of addressing our growing chronic pain crisis, as at least one in five doctor visits are tied to pain,” said Lin Health CEO and Co-Founder Yehuda Kogan. “We’ve proven that our mission-driven team and model deliver results for patients, systems, and payers, and now we’re ready to compound our rapid growth, scale our partnerships, and bring relief to the millions of underserved Americans living with these conditions.”
Yehuda Kogan, CEO and Co-Founder, Lin Health
“Lin Health has built a category-defining approach to chronic conditions as they tackle one of the most costly and overlooked challenges in U.S. healthcare: chronic pain,” said Dan Goldsmith of Proofpoint Capital, who joins Lin Health’s board. “Their model doesn’t just deliver meaningful outcomes for patients; it also addresses systemic inefficiencies and financial realities for payers and care teams. I’ve seen firsthand how the right combination of technology and clinical expertise can transform an industry, and Lin is poised to do just that for pain care. I’m excited to join the board and support the team in scaling this important mission.”
Dan Goldsmith, Proofpoint Capital
